Reata Lays Commercial Path For Skyclarys With First-Ever Friedreich’s Ataxia Nod

 
• By Alaric DeArment

The company forecasts an addressable US patient market that comprises 90% of the total Friedreich’s population of 5,000 based on a broad label covering patients aged 16 and older.

The FDA approved Skyclarys, the first drug for Friedreich's ataxia • Source: Shutterstock

More from New Products

More from Scrip